The efficacy of ␥-secretase inhibitors in vivo has, to date, been generally assessed in transgenic mouse models expressing increased levels of amyloid-␤ (A␤) peptide thereby allowing the detection of changes in A␤ production. However, it is not clear whether the in vivo potency of ␥-secretase inhibitors is independent of the level of amyloid precursor protein expression. In other words, does a ␥-secretase inhibitor have the same effect in nontransgenic physiological animals versus transgenic overexpressing animals? In the present study, an immunoassay has been developed which can detect A␤(40) in the rat brain, where concentrations are much lower than those seen in transgenic mice such as Tg2576 (c. 0.7 and 25 nM, respectively) and in cerebrospinal fluid (CSF, c. 0.3 nM). Using this immunoassay, the effects of the
oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide]
were assessed and robust dose-dependent reductions in rat brain and CSF A␤(40) levels were observed with ID 50 values of 1.3 mg/kg for both brain and CSF. These values were comparable with those calculated for LY-411575 in transgenic mice. Time course experiments using LY-411575 demonstrated comparable temporal reductions in rat brain and CSF A␤(40), further suggesting these two pools of A␤ are related. Accordingly, when all the data for the dose-response curve and time course were correlated, a strong association was observed between the brain and CSF A␤(40) levels. These data demonstrate the utility of the rat as a novel approach for assessing the effects of ␥-secretase inhibitors on central nervous system A␤(40) levels in vivo.
Alzheimer's disease (AD) is one of the major neurological diseases of the elderly, characterized histopathologically by protein deposits in the brain parenchyma (plaques) or blood vessels and intracellular neurofibrillary tangles of abnormally phosphorylated protein. The plaques mainly consist of the A␤ peptides originating from cleavage of the amyloid precursor protein (APP), with the majority being the more hydrophobic A␤(42) which is particularly prone to aggregation (Selkoe 2001) . Furthermore, the identification of APP gene mutations in familial Alzheimer's disease (FAD) cases gives evidence of the involvement of APP processing in AD (Goate et al., 1991; Hardy, 1997) .
The enzymes responsible for processing APP into A␤ are the aspartyl proteases, ␤-amyloid cleaving enzyme (BACE or ␤-secretase) and ␥-secretase (Selkoe and Schenk, 2003) . Although an attractive target for drug discovery, inhibition of ␤-secretase has proved challenging in terms of identification of small molecules for therapeutic use (Selkoe and Schenk, 2003; Middendorp et al., 2004) . As a result, considerable effort has centered on the inhibition of ␥-secretase, an enzyme complex composed of at least four different protein subunits: presenilin (the putative aspartyl protease), nicastrin, APH-1, and PEN-2. ␥-Secretase is responsible for the intramembrane proteolytic cleavage of the C-terminal fragment of APP resulting in mainly A␤(40) or A␤(42) production (reviewed in Selkoe and Schenk, 2003; Haass, 2004) .
There have been a number of reports describing the inhibition of ␥-secretase in vitro, but relatively few describing inhibition in vivo (for review, see Harrison et al., 2004b) . Recently, bioavailable, brain penetrant ␥-secretase inhibitors have permitted the characterization of the reduction of A␤ in vivo (Dovey et al., 2001; Lanz et al., 2003 Lanz et al., , 2004 Wong et al., 2004) . These studies used strains of transgenic mice overexpressing the 695-amino acid isoform of the human APP sequence containing FAD mutations (PDAPP, Games et al., 1995; Tg2576, Hsiao et al., 1996 TgCRND8, Chishti et al., 2001 ) to demonstrate A␤-lowering effects with two different ␥-secretase inhibitors, DAPT and LY-411575. DAPT, a dipeptide, gave dose-dependent decreases of A␤ in the brain, CSF, and plasma of PDAPP and Tg2576 mice (Dovey et al., 2001; Lanz et al., 2003) . More recently, evaluation of the potent lactam
) demonstrated a dosedependent effect in TgCRND8 and Tg2576 mice (Lanz et al., 2004; Wong et al., 2004) .
These FAD mutations result in increases in A␤(42) production and lead to the development of a number of neuropathological hallmarks of AD at various time intervals after birth. Clinically, FAD is only a small percentage of cases, the majority being sporadic AD. Although important as models of amyloidosis, the effect of artificially high A␤ levels on the animal's physiology is unclear at present.
Recently, a study using the inhibitor DAPT revealed less of a reduction in A␤ in guinea pig compared with two strains of transgenic mouse, suggesting nontransgenic animals may respond differently to ␥-secretase inhibitors than transgenic mice (Harrison et al., 2004a) . Therefore, as well as assessing efficacy of ␥-secretase inhibitors in these transgenic mice, it is important to determine whether these inhibitors are as effective in other nontransgenic rodents such as rats. In addition, rats are used preclinically as a toxicology safety species. With concerns raised about pharmacological toxicity resulting from inhibition of ␥-secretase (Searfoss et al., 2003) , being able to determine toxicity and central nervous system efficacy in the same animal is critical to enable determination of therapeutic windows in vivo.
Numerous studies have demonstrated that transport of A␤ in and out of the brain is regulated by different mechanisms such as low-density lipoprotein receptor-related protein (LRP) and receptor for advanced glycation end products (reviewed in Tanzi et al., 2004) . Determining in vivo changes in central nervous system A␤ production resulting from ␥-secretase inhibition will aid understanding of these dynamics in a physiological system.
Although a previous study used immunoprecipitation and Western blotting to ascertain changes in rat brain and CSF A␤ after administration of insulin-like growth factor-1 (Carro et al., 2002) 
Materials and Methods
Chemistry. LY-411575 was prepared in-house by methods as described elsewhere (Wu et al., 1998; Audia et al., 2000) , with the exception that the 5-methyl-5,7-dihydro-6H-dibenzo [b,d] azepin-6-one moiety was prepared by Pd(0)-catalyzed cross-coupling of 2-aminophenylboronic acid with 2-bromophenylacetonitrile, followed by base-mediated hydrolysis, cyclization, and methylation (35% yield, three steps) (Baudoin et al., 2002) .
Animals and Dosing. All procedures were conducted in accordance with the Animals (Scientific Procedures) Act of 1986 and its associated guidelines. Four-to 6-month-old Tg2576 transgenic mice (male and female) overexpressing human APP harboring the Swedish mutation (K670N, M671L; Hsiao et al., 1996) were bred in-house, whereas male Sprague-Dawley rats (250 -300 g) were obtained from Charles River (Manston, Kent, UK). All animals were maintained on a 12-h light/dark cycle with unrestricted access to food and water until use. Rats were dosed orally with a suspension in 0.5% methylcellulose in water at 1 ml/kg.
Pharmacokinetic Measurement of LY-411575. Six male rats, weighing approximately 350 g, were deprived of food overnight. Carotid arteries were cannulated under anesthesia (isoflurane), and each rat was given a 100-unit dose of heparin (0.1 ml, 1000 units/ml) via the cannula. Each cannulated rat was connected to an AccuSampler, an automatic blood sampler (Dilab, Lund, Sweden) , and the rats were allowed to recover for at least 36 h. LY-411575 was administered at 1 mg/kg intravenously to three animals via a bolus injection (1 ml/kg) in PEG300/water 3:1 solution. LY-411575 was also administered at 1 mg/kg orally to the remaining three animals (5 ml/kg) in 0.5% methylcellulose in water as an amorphous suspension. Serial blood samples were collected using the AccuSampler at specified time points up to 24 h after dosing. Plasma was separated by centrifugation and the samples frozen at Ϫ80°C prior to analysis by tandem mass spectrometry.
LY-411575 Analysis. Plasma samples were extracted by protein precipitation using an automated method on a Beckman Biomek 2000 liquid handling robot. The resultant samples were then analyzed using an Agilent 1100 high-pressure liquid chromatography and CTC autosampler interfaced to a Sciex API4000 triple quadruple mass spectrometer (Applied Biosystems, Cheshire, UK). Chromatography was performed on a Kromasil KR100 5C18 column, 150 ϫ 3.2 mm i.d. (Hichrom, Theale, Berkshire, UK) with a mobile phase consisting of 60% acetonitrile in 25 mM ammonium formate buffer at pH 3 and a flow rate of 500 l/min. Injections of 50 l were made with detection of LY-411575 by multiple reaction monitoring of transition 480-239.
The terminal phase rate constant (k el ) was determined by linear regression of the natural log plasma concentration-time profile. The terminal elimination half-life (t 1/2 ) was calculated from 0.693/k el . Area under the plasma concentration-time curve (AUC 0 -⌻ ) was cal-
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at ASPET Journals on May 18, 2017 jpet.aspetjournals.org culated using the linear trapezoid rule and extrapolated to infinity (AUC T-ϱ ) using k el . The mean residence time was calculated as the ratio AUMC/AUC following an intravenous dose, where AUMC is the area under the first moment curve from 0 -ϱ. Systemic clearance was calculated from intravenous data using dose/AUC 0 -ϱ . Volume of distribution was calculated from mean residence time multiplied by systemic clearance. Oral bioavailability was calculated from the ratio of AUC 0 -ϱ values after oral and intravenous doses.
Tissue Sample Preparation. Tg2576 mice were euthanized by stunning followed by decapitation. Rats were anesthetized using isoflurane and CSF removed by puncturing the cisterna magna with a 21G butterfly cannula and then euthanized by decapitation. Brains were removed and, along with the CSF, immediately frozen on dry ice and stored at Ϫ80°C until use. CSF samples with visible blood contaminants were discarded.
The frozen brains were homogenized in 10 volumes (w/v) of 0.2% diethylamine (DEA) containing 50 mM NaCl (pH 10) and protease inhibitors (Roche Diagnostics, Mannheim, Germany) (Savage et al., 1998) , then centrifuged at 355,000g, 4°C for 30 min (Beckman Coulter Ultracentrifuge, Optima Max; Beckman Coulter, Fullerton, CA). The resulting supernatant was retained as the soluble fraction and neutralized by addition of 10% 0.5 M Tris/HCl, pH 6.8. Samples were frozen at Ϫ80°C awaiting analysis.
Prior to analysis, the CSF was thawed, centrifuged at 2300g, and the supernatant was diluted 1:4 with PBS, 2% bovine serum albumin (BSA), 0.5% Tween 20 (Sigma Chemical, Poole, Dorset, UK), plus protease inhibitors.
Measurement of A␤(40).
In this study, monoclonal antibodies G2-10 (Ida et al., 1996) were used with biotinylated antibody 4G8 (Signet Laboratories, Dedham, MA; Kim et al., 1988) to detect A␤ peptides in solution ending at residue 40, with negligible crossreactivity. These species, referred to as A␤ (40), reflect subpopulations of peptides with heterogeneous N-termini encompassing at least the 4G8 epitope at residues 17-24.
Analysis of the samples was performed using the Meso Scale Discovery (MSD) Sector Imager 6000 (Meso Scale Discovery, Gaithersburg, MD). The MSD methodology is essentially an immunoassay which utilizes electrochemiluminescence (ECL) to measure protein levels. The A␤(40) (California Peptide Research, Inc., Napa, CA) standards were generated from a 100 M stock in dimethyl sulfoxide diluted into BSA buffer [2% BSA, 0.5% Tween 20 in PBS (Sigma Chemical) plus protease inhibitors (Roche Diagnostics)]. Twenty-five microliters of 4G8-biotinylated antibody at 4 g/ml (capture antibody; Signet Laboratories) were added to an avidin-coated multiarray 96-well plate and incubated on a plate shaker (Heidolph titramax 100) at 600 rpm overnight at 4°C. The plates were then washed three times with 200 l of PBS and 100 l of blocking buffer solution (100 ml H 2 O, 6 g of blocker A, 20 ml of blocking buffer A) added to all wells. The plates were then sealed, wrapped in tin foil, and incubated at room temperature on a plate shaker (600 rpm) for 1 h. At the end of the incubation, the wells were washed three times with 200 l of PBS. Twenty-five microliters of the standards or samples were then added to the wells followed by G210 antibody at 1 g/ml (licensed from the University of Heidelberg, Heidelberg, Germany) labeled with a Ruthenium (II) trisbipyridine N-hydroxysuccinimide ester which, when in close proximity to the bottom of the well, emits light following electrical stimulation of the plate. The plates were then aspirated and washed three times with PBS. Finally, MSD-S read buffer was added to the plates, and they were read on the Sector Imager 6000. To correct for nonspecific effects of the brain assay, brains taken from transgenic mice deficient in APP (Zheng et al., 1996 ; APP-KO) were also processed similarly to the experimental groups, and extracts were included on each plate (supplied by Taconic Farms, Germantown, NY). The counts from these samples (nonspecific) were subtracted from all samples and standards to give specific counts.
Statistical Analysis. Standard curves generated from known concentrations of synthetic A␤(40) were logged to remove bias from high concentration counts and values for brain and CSF A␤(40) interpolated using y ϭ mx ϩ c. Groups were analyzed using two-and one-way analysis of variance and where appropriate, post hoc Dunnett's t test with vehicle/control group or Bonferroni's t test between experimental groups applied (Prism 3.00, GraphPad Software Inc., San Diego, CA).
Results
Assay Characterization. Concentrations of A␤(40) in CSF-and DEA-extracted brain tissue for vehicle-treated animals were typically in the upper mid range of the standards in both the logged and linear graphs (Fig. 1a and insert) with the limit of detection usually about 1 to 3 pM. The signal-tonoise ratio of the vehicle samples with respect to APP-KO samples was usually about 6 (Fig. 1b) . The intra-assay variability of the immunoassay was typically about 5%, whereas interassay variability was approximately 15%, both were assessed using control tissue from naive rats.
Comparison of A␤(40) Levels between the Rat and Transgenic Mice. The concentrations of A␤(40) measured in CSF and DEA-extracted rat brain was approximately 0.3 and 0.7 nM, respectively ( Table 1 ). The value for brain A␤(40) in the rat is about 35 times lower than in-house data generated for brain A␤(40) levels in 3-to 5-month-old Tg2576 mice using the same extraction and immunoassay protocol ( Table  1 ). The ratio of brain A␤(40) to CSF A␤(40) in the rat was about 2.3. Overall, despite much lower levels of A␤ in the rat compared with transgenic mice using the immunoassaybased technology, we were able to consistently measure both brain and CSF A␤(40).
Pharmacokinetic Parameters of LY-411575 in the Rat. To determine whether LY-411575 had comparable pharmacokinetic in rats to the published Tg2576 mouse data (Lanz et al., 2004) , 1 mg/kg was dosed to male rats. Plasma C max was 11 Ϯ 6 nM, T max was about 30 min, and the t 1/2 was calculated to be about 2 h. The plasma concentration from a 10 mg/kg dose at 4 h was 633 Ϯ 81 nM, whereas the brain concentration was 117 Ϯ 22 nM (mean Ϯ S.E.M).
Dose-Related Reduction of Rat Brain and CSF A␤(40) by LY-411575.
To determine whether the levels of 〈␤(40) in the rat brain and CSF could be reduced by inhibition of ␥-secretase in vivo, a dose-response experiment was performed in male Sprague-Dawley rats using the potent ␥-secretase inhibitor LY-411575 (Fig. 2) .
Robust dose-dependent reductions in A␤(40) levels were demonstrated in both the brain and CSF with increasing dose. Complete reduction was obtained in the brain at 10 and 30 mg/kg (i.e., the assay signal was reduced to background levels as defined by the signal obtained in APP-KO mouse brain tissue). The levels of A␤(40) in the CSF were not completely reduced to zero (APP-KO CSF was not available to account for nonspecific signal), although the reductions did not significantly increase between 10 and 30 mg/kg.
To determine whether the reductions in CSF A␤(40) tracked the reductions in brain A␤(40) levels, ID 50 values were calculated using the dose-response data (Fig. 2, a and  b) . The ID 50 for the rat was 1.3 mg/kg for both brain and CSF (Table 2) .
Time Course Data. To determine whether the reductions in brain and CSF A␤(40) were maintained with time, two separate time course experiments using 3 and 10 mg/kg doses of LY-411575 were conducted. At both 3 and 10 mg/kg, the reductions in the CSF A␤(40) levels at 4 h were comparable with those seen in the dose-response curve (p Ͼ 0.05, Fig. 3 versus Fig. 2 ). Both doses of LY-411575 had significant effects on A␤(40) levels in the brain (Fig. 3 , a and b: 3 mg/kg, F ϭ 47.96, p Ͻ 0.0001; 10 mg/kg, F ϭ 42.06, p Ͻ 0.0001) and CSF (Fig. 3 , a and b: 3 mg/kg, F ϭ 18.75, p Ͻ 0.0001; 10 mg/kg, F ϭ 41.28, p Ͻ 0.0001).
In the 3 mg/kg time course, the maximum reduction of A␤(40) by LY-411575 was seen by 8 h in both CSF and brain (p Ͻ 0.001 compared with vehicle levels). The levels of both brain and CSF A␤(40) had begun to rise at 16 h and had returned to vehicle levels by 24 h postdose. When normalized to account for the difference in levels, analysis by two-way analysis of variance (Fig. 3) revealed an effect of time on the A␤(40) levels (p Ͻ 0.0001) and tissue (CSF versus brain, p Ͻ 0.0001) with a significant interaction between them (p Ͻ 0.001). This was borne out in the post hoc analysis because there was a significant difference between brain and CSF levels at 1 and 2 h (t ϭ 5.11, p Ͻ 0.001 and t ϭ 3.56, p Ͻ 0.01, respectively) suggesting a time lag between the brain reduc- tions and CSF. However, from 4 h on, there was no difference in the reductions between brain and CSF A␤(40).
With the 10 mg/kg time course, maximum reductions of A␤(40) levels by LY-411575 were seen by 4 h in both CSF and brain. These reductions did not significantly change in either the CSF or brain up to 24 h postdose (Fig. 3b) .
Correlation between Brain and CSF A␤(40) Levels. To determine whether the reduction of A␤ (40) in the CSF paralleled the brain A␤(40) reduction, the values for brain and CSF from the dose-response and time course experiments were correlated using linear regression analysis (Fig.  4) . When all the values were included, the data demonstrated a good correlation (F ϭ 226.5, p Ͻ 0.0001) and good fit of the data to the line (r 2 ϭ 0.69). However, if the 1-and 2-h points from the 3 mg/kg time course were excluded (open circles, due to there being a time lag) there was a better fit of the data (r 2 ϭ 0.79).
Discussion
Evidence from clinical studies (Wang et al., 1999; Naslund et al., 2000) , in vitro experiments (Lambert et al., 1998; Hartley et al., 1999; Chromy et al., 2003) , and in vivo experiments (Shin et al., 1997; Hsia et al., 1999) suggest that the initial pathogenesis of AD is due to the build up of neurotoxic aggregates of the soluble A␤ peptide species A␤(1-40) and A␤(1-42). As a result, a number of therapeutic approaches for lowering amyloid are in progress, one of which is the use of ␥-secretase inhibitors (Hardy and Selkoe, 2002; Harrison et al., 2004b) . With the advent of orally available ␥-secretase inhibitors, studies in transgenic mice using these inhibitors have demonstrated reductions of A␤ levels in the brain, CSF, and plasma (Dovey et al., 2001; Lanz et al., 2003 Lanz et al., , 2004 Wong et al., 2004) . However, these models have high levels of A␤ not representative of normal physiological rodent levels.
A previous study used immunoprecipitation and Western blotting to determine the effect of insulin-like growth factor on changes of A␤ in the brain and CSF of rats, although the semiquantitative nature of this assay limits this technique (Carro et al., 2002) . In the present study, we have established an immunoassay used to determine whether reproducible reductions in A␤ levels could be demonstrated in the rat in response to administration of the ␥-secretase inhibitor LY-411575 in a comparable way to that seen in transgenic mice (Lanz et al., 2004; Wong et al., 2004) .
A number of studies have investigated the concentrations of A␤ peptide obtained from brain following different extraction methods in transgenic mice and human post-mortem tissue (Wang et al., 1999; Kawarabayashi et al., 2001; Lewis et al., 2004) . The study here examined A␤ extracted from rat brain using DEA. In normal aging human brains, sequential extraction using Tris buffer saline, radioimmunoprecipitation assay buffer, and formic acid extracted a total of about 1 nM of A␤ (40) (Wang et al., 1999) , levels similar to those extracted from rat brain using DEA (see Table 1 ). The levels of A␤ extracted change as both Tg2576 mice and humans begin to develop plaques, with the amount of total A␤ extracted by formic acid increasing with plaque burden (Wang et al., 1999; Kawarabayashi et al., 2001 ). The difficulty of comparing absolute levels across studies due to different extraction and antibody methods has been discussed previously (Lewis et al., 2004) . However, taking these caveats into account we can conclude that the levels seen in the rat are significantly lower than those reported for transgenic mice ranging from 35 to 600 times in the brain and about 15 to 40 times in CSF (see Table 1 ). Interestingly, despite these dif- ferences, the ratio of brain to CSF A␤(40) in the rat was about 2.3, similar to the 1.9 seen in the Tg2576 mouse. Thus, it is possible using this immunoassay system to quantifiably compare effects of ␥-secretase inhibitors in the rat with different species both nontransgenic and transgenic. LY-411575 caused a dose-dependent reduction of A␤ (40) in the brains of TgCRND8 and Tg2576 mice, with a maximal effect between 3 and 6 h (Lanz et al., 2004; Wong et al., 2004) . A dose-response study conducted with LY-411575 at 4 h in the rat demonstrated a dose-dependent reduction of brain A␤(40) with 30 mg/kg causing complete reduction.
The pharmacokinetic profile of LY-411575 in the rat was very similar to the transgenic mouse with a 1 mg/kg oral dose, despite different dosing vehicles. The 10 mg/kg dose gave slightly higher plasma and brain drug concentrations at 4 h in the rat compared with 10 mg/kg at 3 h in the Tg2576 mouse (Lanz et al., 2004) suggesting better bioavailability of LY-411575 in the rat compared with the mouse. Therefore, changes in the pharmacodynamics of A␤ between the mouse and rat are unlikely to be related to the pharmacokinetic profile of the compound.
Previous studies have demonstrated that changes in CSF A␤ correlated with changes in brain A␤ in the transgenic mouse (Lanz et al., 2004) and disease state in humans (Mehta et al., 2000; Maruyama et al., 2001) . The rat has the added advantage of having easily accessible CSF for collection and measurement of A␤ involving relatively simple sampling techniques compared with the mouse (DeMattos et al., 2002) . The dose-response data for LY-411575 demonstrated that a good correlation between CSF and brain A␤(40) also holds true in the rat. To further characterize the dynamics of this relationship, time course experiments using a high dose (10 mg/kg) and low dose (3 mg/kg) of LY-411575 were performed. At 10 mg/kg, both the CSF and brain were maximally reduced by 4 h, in keeping with data seen in the transgenic mice (Wong et al., 2004) . Interestingly, at the lower dose, there appeared to be a slight lag between the reduction of A␤(40) in the brain and CSF at the early time points, although after this time point the levels in CSF and brain followed each other very closely. Since no lag is seen in the higher dose, it needs to be investigated further whether this is truly significant.
These results appear to contrast with the studies in the Tg2576 mouse, where 1 mg/kg was dosed to Tg2576 and brain and CSF A␤(40) taken at 3, 9, and 24 h (Lanz et al., 2004) . The authors observed that both CSF and brain A␤(40) were reduced similarly at 3 h and then the CSF appeared to recover more quickly than brain A␤(40) by 9 h with CSF A␤(40) recovering fully and brain A␤(40) partially recovered by 24 h. The lack of time points earlier than 3 h make comparisons between the studies difficult, and if the rat 3 mg/kg data were replotted without the 1-and 2-h points, then the reductions in the brain and CSF would parallel each other without an apparent lag. The recovery noted in the Tg2576 mice at 9 h was not seen in the rat at 8 h, although this is unlikely to be due to the difference in time points. One explanation for the difference could be that the Tg2576 mouse study used guanidine hydrochloride extraction, whereas the present study used DEA.
It has been shown that the DEA extraction contains very little membrane-associated C99 or APP compared with guanidine hydrochloride extraction (Savage et al., 1998) and may reflect different pools of A␤ (soluble versus deposited/aggregated, as well as possibly extracellular versus intracellular). Thus, the DEA method may be extracting A␤ from a pool similar to CSF A␤, although it would be interesting to investigate whether the pharmacodynamics of A␤ change using different extraction protocols in the rat. However, using this extraction protocol the strong association seen between the two compartments when these data were correlated reinforces the idea that CSF A␤(40) can be used as a bona fide biomarker for brain A␤(40) levels for this type of dosing regime.
As well as the relationship between brain and CSF, the mechanism of A␤ transport into and out of the brain via the blood-brain barrier is of significant interest. Of these, receptor for advanced glycation end products and LRP have been proposed as major candidates in this process (reviewed in Tanzi et al., 2004) . It has been demonstrated that removal of A␤(1-40) from the brain to the plasma is very rapid and appears to be regulated by LRP (Shibata et al., 2000) . Furthermore, at a low dose of 0.1 mg/kg, the Tg2576 mouse showed an increase in plasma A␤ without effects on brain or CSF A␤ (Lanz et al., 2004) . The importance of these findings make the generation of an assay able to measure picomolar levels of A␤ expected in the rat plasma an important future objective.
It has also been shown that A␤(1-40) and A␤(1-42) appear to have differential transport with LRP favoring clearance of A␤(1-40) (Deane et al., 2004) . Again, being able to determine the relationship between different species of A␤, especially A␤(1-42) in the rat as a result of ␥-secretase inhibition, would be important in understanding the relationship of different isoforms of A␤ in a physiological model.
In addition to its role in processing APP, ␥-secretase is involved in other regulatory functions. One of the best characterized is control of the Notch pathway, which has been implicated in a number of functions, including peripheral organ toxicity (Searfoss et al., 2003; Wong et al., 2004) . Since the rat is widely used as a safety species, the ability to measure brain and CSF A␤(40) in the rat allows quantitative efficacy-toxicity relationships to be derived in a nontransgenic species. 
Downloaded from
In summary, the current study demonstrates the utility of the rat as an alternative model for investigating the effects of therapeutic A␤-lowering agents. These data also further reinforce observations made in previous studies that CSF A␤ levels are markers of central A␤ reduction (Lanz et al., 2004) . Furthermore, the use of the rat as a preclinical model allows an effective means of measurement of efficacy and toxicity to be combined in one animal model thereby reducing the number of animals used and allowing therapeutic windows to be determined before clinical studies begin.
